EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 7.065

ICV - 79.57

Abstract

EFFICACY OF ONABOTULINUM TOXIN IN THE TREATMENT OF CHRONIC MIGRAINE

Dr. Garima Dabas* and Dr. Sahil Gupta

ABSTRACT

Chronic migraine (CM) is a disabling headache characterized by characteristic throbbing quality, moderate to severe intensity, unilateral headache associated with photophobia, phonophobia, and gastrointestinal distress. Episodic migraine occurs less than 15 days per month, while chronic migraines occur more or equal to 15 days per month. Treatment includes acetaminophen, aspirin, and NSAIDs for mild attacks and triptans for severe attacks. Preventive daily treatment of migraine is recommended when migraine episodes exceed 6–8 days per month, or what is tolerable to the patient and includes beta-blockers, topiramate, amitriptyline, and divalproex sodium. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox®) for the prophylactic treatment of CM in 2010 as onabotulinumtoxinA is effective in reducing the frequency and severity of chronic migraine. This article reports on the efficacy of onabotulinumtoxinA in treatment of CM.

Keywords: Botulinum neurotoxin, chronic migraine, onabotulinum toxin A, chronic headache.

[Full Text Article] [Download Certificate]